Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa
January 29, 2018 08:45 ET
|
Abeona Therapeutics Inc.
First gene therapy RMAT designation for Epidermolysis BullosaEnables accelerated approval path and real world data usage NEW YORK and CLEVELAND, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Abeona...
Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights
November 15, 2017 08:25 ET
|
Abeona Therapeutics Inc.
Investor Conference Call to be held Monday, November 20th at 10:00 am ETGlobal enrollment continues in ABO-102 trial for MPS IIIAScreening initiated in ABO-101 Phase 1/2 trial for MPS IIIBPivotal...
Abeona Management to Present at Multiple Conferences in November
November 13, 2017 08:45 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, Ohio
October 04, 2017 08:45 ET
|
Abeona Therapeutics Inc
-- Facility to support development of advanced gene and cell therapies for treatment of life-threatening rare diseases -- Leaders from local government, life sciences and medical technology to...
Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A
August 16, 2017 09:25 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies...
Abeona Therapeutics Announces Appointment of Juan Ruiz as Chief Medical Officer
July 25, 2017 08:05 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, July 25, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy Program
June 29, 2017 08:15 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, June 29, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
ABEO LOSS NOTICE: Rosen Law Firm Reminds Abeona Therapeutics Inc. Investors of Important Feb. 14 Deadline in Class Action - ABEO
January 24, 2017 19:56 ET
|
The Rosen Law Firm PA
NEW YORK, Jan. 24, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of: (1) PlasmaTech Biopharmaceuticals, Inc. securities from March 31, 2015 through...
INVESTOR LOSS ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Abeona Therapeutics Inc. - ABEO
January 05, 2017 13:50 ET
|
The Rosen Law Firm PA
NEW YORK, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of: (1) PlasmaTech...